CytomX Therapeutics (CTMX) vs DiaMedica Therapeutics (DMAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
DiaMedica Therapeutics (DMAC) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 8.1% versus a loss of 47.7%. Over five years, DMAC leads with a +118.8% price change compared with -69.9% for CTMX. DiaMedica Therapeutics is the larger company by market cap ($445.1 million vs $442.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTMX | DMAC |
|---|---|---|
| Share price | $2.03 | $8.25 |
| Market cap | $442.55M | $445.15M |
| 1-day change | -0.98% | +2.87% |
| YTD return | -52.35% | +3.64% |
| 1-year return | -47.68% | +8.13% |
| 5-year return | -69.93% | +118.83% |
| EPS (TTM) | $-0.51 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $76.20M | — |
| Revenue growth (YoY) | -44.82% | — |
| Net income (latest FY) | $-17.37M | $-32.77M |
| Operating margin | -29.35% | — |
| Net margin | -22.79% | — |
| 52-week high | $8.21 | $11.00 |
| 52-week low | $1.87 | $5.25 |
| Distance from 52-week high | -75.27% | -25.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +509.85% | +96.97% |
| Average volume | 4.27M | 210.46K |
| Shares outstanding | 218.00M | 53.96M |
| Employees | 69 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMAC has outperformed CTMX by 55.8 percentage points over the past year.
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
CTMX vs DMAC FAQ
Which is bigger, CytomX Therapeutics or DiaMedica Therapeutics?
DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $445.15M compared with $442.55M for CytomX Therapeutics (CTMX).
Which stock has performed better over the past year, CTMX or DMAC?
DMAC returned +8.13% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are CytomX Therapeutics and DiaMedica Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.